Gastroparesis Treatment Market Set for Robust Growth, Projected to Reach US$ 10.3 Billion by 2034

The Global Gastroparesis Treatment Market (위마비 치료 시장) is poised for substantial growth over the next decade, driven by increasing diabetes prevalence and continuous drug discovery and development. According to a new market analysis, the industry, valued at US$ 6.3 billion in 2023, is expected to grow at a CAGR of 4.6% from 2024 to 2034, reaching an estimated US$ 10.3 billion by the end of 2034.

Download Sample PDF from Here: https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=39305&utm_source=Openpr&utm_medium=Amit

Market Dynamics and Key Drivers
The primary factor propelling the gastroparesis treatment market is the rising incidence of diabetes globally. Gastroparesis, a condition that disrupts the normal movement of muscles in the stomach, is commonly linked to diabetes, leading to symptoms such as nausea, vomiting, and abdominal pain. The growing number of diabetic patients worldwide necessitates effective treatments for managing gastroparesis, thereby driving market growth.

Additionally, significant investments by pharmaceutical companies in research and development are contributing to the continuous influx of new drug candidates. Many of these drugs are in the pipeline, supported by funding from both government and non-government agencies, aiming to regularize digestive processes disturbed by conditions like constipation, irritable bowel syndrome, or diabetes.

Industry analysts highlight the ongoing research and development efforts as crucial for market expansion. The promising results from clinical trials of new drug candidates have prompted regulatory authorities, such as the U.S. FDA, to expedite the approval process, facilitating quicker access to innovative treatments for patients.

The Institute for Health Metrics and Evaluation (IHME) forecasts a significant rise in diabetes cases, from 529 million to 1.3 billion by 2050. This increase underscores the urgent need for effective gastroparesis treatments, as diabetes is a leading cause of gastroparesis.

Recent Developments and Innovations
Several notable developments have taken place in the gastroparesis treatment landscape:
1. Deudomperidone Phase II Trials: In May 2024, Deudomperidone entered Phase II trials for diabetic gastroparesis. CinDome Pharma, the developer, secured US$ 40 million in Series B financing to advance this potential treatment.
2. Gastric Peroral Endoscopic Myotomy: Studies presented at the 2023 Annual Meeting of the American College of Gastroenterology indicated that this procedure could benefit patients with persistent gastroparesis.
3. Aclipse Therapeutics Agreement: In September 2023, Aclipse Therapeutics and its subsidiary, Aclipse Two, Inc., signed a licensing agreement with Chong Kun Dang Pharmaceutical Corporation (CKD) for the global rights to develop lobeglitazone for gastroparesis and other conditions.

Access Full Report from Here - https://www.transparencymarketresearch.com/gastroparesis-treatment-market.html

Regional Insights
North America leads the gastroparesis treatment market, (Markt für die Behandlung von Gastroparese) with the U.S. contributing significantly due to its large pre-diabetic population and favorable reimbursement policies. According to the CDC, 96 million adults in the U.S. had prediabetes in June 2022, accounting for 38% of the adult population. Furthermore, the Immune Deficiency Foundation (IDF) reports that nearly 51 million people in the Caribbean and North America were living with diabetes in 2021, with numbers expected to rise to 63 million by 2045.

Canada is also witnessing an increase in diabetes cases, with Diabetes Canada projecting a rise from 5,719,000 individuals in 2022 to 7,277,000 by 2032. This growing diabetic population necessitates effective gastroparesis treatments, further driving market growth in the region.

Key Market Players
Prominent companies in the gastroparesis treatment market are actively conducting clinical trials to strengthen their market positions. Key players include Abbott Laboratories, AbbVie Inc., AstraZeneca plc, Bayer AG, Cipla Limited, Evoke Pharma, Pfizer Inc., Salix Pharmaceuticals, Inc., The Takeda Pharmaceutical Company Limited, and Teva Pharmaceutical Industries Ltd.
These companies are profiled based on their business strategies, financial performance, product portfolios, and market segments. For instance, in February 2022, Vanda Pharmaceuticals Inc. announced positive results from its Phase III clinical trial, VP-VLY-686-3303, demonstrating the safety and effectiveness of tradipitant in treating gastroparesis symptoms.

Future Outlook
The gastroparesis treatment market is expected to continue its upward trajectory, driven by the increasing prevalence of diabetes, continuous drug discovery, and development efforts. With regulatory authorities fast-tracking the approval of promising drug candidates and companies investing heavily in R&D, the market is well-positioned for robust growth over the next decade.

Click Here to Purchase this Comprehensive Insights Report: https://www.transparencymarketresearch.com/checkout.php?rep_id=39305<ype=S&utm_source=Openpr&utm_medium=Amit

More Trending Reports-

Pediatric Radiology Market (Marché de la radiologie pédiatrique): https://www.transparencymarketresearch.com/pediatric-radiology-market.html

Veterinary Imaging Market (獣医用画像市場): https://www.transparencymarketresearch.com/veterinary-imaging-market.html

About Us Transparency Market Research:

Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. The firm scrutinizes factors shaping the dynamics of demand in various markets. The insights and perspectives on the markets evaluate opportunities in various segments. The opportunities in the segments based on source, application, demographics, sales channel, and end-use are analysed, which will determine growth in the markets over the next decade.

Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision-makers, made possible by experienced teams of Analysts, Researchers, and Consultants. The proprietary data sources and various tools & techniques we use always reflect the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in all of its business reports.

Contact Us:

Transparency Market Research Inc.
CORPORATE HEADQUARTER DOWNTOWN,
1000 N. West Street,
Suite 1200, Wilmington, Delaware 19801 USA
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Website: https://www.transparencymarketresearch.com
Blog: https://tmrblog.com
Email: sales@transparencymarketresearch.com

This release was published on openPR.